Insmed (INSM) Misses Q3 EPS by 1c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Insmed (INSM) Misses Q3 EPS by 1c, Revenues Beat

Insmed Reports Third Quarter 2019 Financial Results and Provides Business Update

October 30, 2019 7:30 AM EDT

BRIDGEWATER, N.J., Oct. 30, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 2019 and provided a business update.  

"We remain very pleased with the continued strong performance of the US launch of ARIKAYCE® (amikacin liposome inhalation suspension). Insmed remains guided by our desire to have a positive impact on patients' lives and is powered by our shared sense of purpose to deliver therapies to small patient populations... More